Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The neurologist and assistant professor at the University of Toronto provided insight on the recently announced positive topline findings from the phase 3 Clarity AD study of lecanemab (BAN2401) in early Alzheimer disease.
In this NeurologyLive® Peer Exchange episode, Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, share their hopes about the evolution of future multiple sclerosis care and express their gratitude for the next generation of neurologists.
In the latest edition of our in-depth Q&A series, the professor of neurology and pediatrics at the University of Rochester Medical Center provided insight on the emerging therapies and advancements for treating patients with Duchenne muscular dystrophy.
Ashgan Elshinawy, DO, a pulmonologist at Penn Medicine, assessed the current ways to treat patients with insomnia and the areas of needed improvement. Elshinawy provided insight on treatments such as cognitive behavioral therapy, the need for patience when managing the condition, and the potential to overhaul care going forward.
The American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting may be over, but the latest in neuromuscular, musculoskeletal, and electrodiagnostic medicine is all included in NeurologyLive®'s coverage, which has continued through the week.